Product
NKX019
1 clinical trial
11 indications
Indication
lymphomaIndication
Non-HodgkinIndication
B-cell Acute Lymphoblastic LeukemiaIndication
Diffuse Large B-cell LymphomaIndication
mantle cell lymphomaIndication
Indolent LymphomaIndication
Waldenstrom MacroglobulinemiaIndication
Chronic Lymphocytic LeukemiaIndication
Small Lymphocytic LymphomaIndication
Aggressive LymphomaIndication
Large-cell LymphomaClinical trial
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell MalignanciesStatus: Recruiting, Estimated PCD: 2024-08-01